SEE THE OPZELURA DIFFERENCE

TREATMENT SUCCESS (IGA-TS*) ACHIEVED AT WEEK 81

At baseline, patient 1’s knee shows visible red patches, indicating inflammation and lesions associated with AD. At week 2 of treatment, red patches have begun to clear. At week 8, patient has clearer skin with less inflammation and no visible lesions.
At baseline, patient 1’s knee shows visible red patches, indicating inflammation and lesions associated with AD. At week 2 of treatment, red patches have begun to clear. At week 8, patient has clearer skin with less inflammation and no visible lesions.

Actual clinical trial participant. Individual results may vary.

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.2

TREATMENT SUCCESS (IGA-TS*) ACHIEVED AT WEEK 81

At baseline, patient 2’s hip shows visible red patches, indicating inflammation and lesions associated with AD. At week 2 of treatment, red patches have begun to clear. At week 8, patient has clearer skin with less inflammation and no visible lesions.
At baseline, patient 2’s hip shows visible red patches, indicating inflammation and lesions associated with AD. At week 2 of treatment, red patches have begun to clear. At week 8, patient has clearer skin with less inflammation and no visible lesions.

Actual clinical trial participant. Individual results may vary.

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.2

View itch data >

IGA=Investigator's Global Assessment; IGA-TS=Investigator's Global Assessment Treatment Success.

References: 1. Data on file. Incyte Corporation. 2021. 2. Opzelura. Prescribing Information. Incyte Corporation; 2021.